Clinical Trial Update: A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease [Phase 2, Phase 3]

View source ↗

Summary

Ocugen's Phase 2/3 study of OCU410ST for Stargardt Disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• OCU410ST

Snippet

Sponsor: Ocugen | Conditions: Stargardt Disease | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING